Conjugated
Estrogens (Premarin) |
Category:
Description:
Indications:
-
Menopausal
vasomotor symptoms (hot flashes, etc.)
-
Atrophic
vaginitis and kraurosis vulvae
-
Female
hypogonadism
-
Female
castration and primary ovarian failure
-
Breast
cancer (palliation only)
-
Prostatic
carcinoma
-
Osteoporosis
prophylaxis
-
Postpartum
breast engorgement
-
Abnormal
uterine bleeding due to hormonal imbalance
Contraindications:
-
Known
or suspected breast cancer (except those being treated for metastatic
disease)
-
Known
or suspected estrogen-dependent neoplasia
-
Known
or suspected pregnancy
-
Undiagnosed
abnormal genital bleeding
-
Current
or history of thrombophlebitis, thrombosis, thromboembolic disorders
(except when used in breast or prostatic cancer treatment).
Precautions:
-
Pregnancy
category X
-
Use
with caution in nursing mothers and patients with hypertension,
diabetes, asthma, epilepsy, migraine, cardiac or renal dysfunction,
history of depression, pre-existing uterine leiomyotoma, history of
jaundice during pregnancy, impaired liver function, metabolic bone
disorders and in young women (and men).
-
Take
with food to avoid GI side effects.
-
May
decrease glucose intolerance in diabetic patients.
-
Discontinue
therapy and contact health care provider if pregnancy is suspected.
Adverse
Reactions (Side Effects):
-
Rash,
acne, alopecia, hirsutism
-
Abnormal
menstrual bleeding, changes in cervical secretions
-
Edema,
weight change
-
Depression,
insomnia, somnolence
-
Nausea
|
Dosage:
-
Administered
orally, vaginally and IV injection
-
Menopausal
vasomotor symptoms: 1.25mg per day
-
Atrophic
vaginitis and kraurosis vulvae: 0.3-1.25mg orally, intravaginally and
topically per day depending on tissue response
-
Female
hypogonadism: 2.5-7.5mg per day in divided doses for 20 days, then
rest for ten days, then repeat schedule until bleeding occurs
-
Female
castration and primary ovarian failure: 1.25mg per day cyclically,
adjusted to lowest dose for individual
-
Breast
cancer (palliation only): 10mg tid for at least three months
-
Prostatic
carcinoma: 1.25-2.5mg tid
-
Osteoporosis
prophylaxis: 1.25mg per day, cyclically
-
Postpartum
breast engorgement: 3.75mg q4h for 5 doses or 1.25mg q4h for 5 days
-
Abnormal
uterine bleeding due to hormonal imbalance: 25mg IM or IV injection,
repeat in 6-12 hours if needed
For more information on the use of conjugated estrogens, read:
|
|
|
|
The information contained here is an
abbreviated summary. For more detailed and complete information, consult the
manufacturer's product information sheets or standard textbooks
Source: Operational Medicine 2001, Health
Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau
of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington,
D.C., 20372-5300
This information is provided by The Brookside Associates. The Brookside
Associates, LLC. is a private organization, not affiliated with any governmental
agency. The opinions presented here are those of the author and do not
necessarily represent the opinions of the Brookside Associates or the Department
of Defense. The presence of any advertising on these pages does not constitute
an endorsement of that product or service by either the US Department of Defense
or the Brookside Associates. All material presented here is unclassified.
C. 2009, 2014, All Rights Reserved
|
|